Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00208208 · ClinicalTrials.gov registry record · Phase 4
Geodon (Ziprasidone) for Posttraumatic Stress Disorder
A Phase 4 study, sponsored by Creighton University.
- Completed
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
NCT00208208: Completed Phase 4 study, sponsored by Creighton University.
NCT00208208 is a Phase 4 study that has completed, run by Creighton University. The registered enrollment target is 80 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00208208, a Phase 4 study, has completed, sponsored by Creighton University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
Study Summary
Atypical antipsychotics have shown promise in the treatment of depression and anxiety, which are prominent symptoms of PTSD. The profile of the atypical antipsychotic, ziprasidone (Geodon), suggests possible anxiolytic and antidepressant properties. This research will assess the potential effectiveness of Geodon in civilian men and women who suffer from severe PTSD. Response to ziprasidone or placebo will be measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8).
Interventions
- DRUG Ziprasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2002-12 |
| Est. Completion | 2005-04 |
| Phase | Phase 4 |
What the finished NCT00208208 record still lists
NCT00208208 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Ziprasidone is the first listed.
NCT00208208 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00208208 about?
NCT00208208 is a clinical study titled "Geodon (Ziprasidone) for Posttraumatic Stress Disorder". Atypical antipsychotics have shown promise in the treatment of depression and anxiety, which are prominent symptoms of PTSD. The profile of the atypical antipsychotic, ziprasidone (Geodon), suggests possible anxiolytic and antidepressant properties. This research will assess the potential effectiven...
What is the current status of trial NCT00208208?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2002-12. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00208208?
The interventions under investigation include: Ziprasidone (DRUG).
Who is sponsoring clinical trial NCT00208208?
This trial is sponsored by Creighton University, which has 98 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00208208's enrollment target sits among peer trials
80 946th of 2000 higher than 1,021 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia